SELLAS Life Sciences (SLS) Accumulated Expenses (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Accumulated Expenses for 9 consecutive years, with $5.5 million as the latest value for Q3 2024.
- Quarterly Accumulated Expenses fell 20.77% to $5.5 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Sep 2024, down 20.77% year-over-year, with the annual reading at $7.6 million for FY2023, 21.7% up from the prior year.
- Accumulated Expenses for Q3 2024 was $5.5 million at SELLAS Life Sciences, up from $5.2 million in the prior quarter.
- The five-year high for Accumulated Expenses was $7.6 million in Q4 2023, with the low at $888000.0 in Q1 2020.
- Average Accumulated Expenses over 5 years is $4.1 million, with a median of $3.0 million recorded in 2022.
- The sharpest move saw Accumulated Expenses surged 186.82% in 2021, then dropped 20.77% in 2024.
- Over 5 years, Accumulated Expenses stood at $1.9 million in 2020, then surged by 38.0% to $2.6 million in 2021, then skyrocketed by 138.11% to $6.3 million in 2022, then rose by 21.7% to $7.6 million in 2023, then decreased by 28.24% to $5.5 million in 2024.
- According to Business Quant data, Accumulated Expenses over the past three periods came in at $5.5 million, $5.2 million, and $6.5 million for Q3 2024, Q2 2024, and Q1 2024 respectively.